- Home
- ACEL vs XERS Comparison
ACEL vs XERS Comparison
Compare ACEL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACEL | XERS |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.0M | 1.0B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACEL | XERS |
|---|---|---|
| Price | $11.61 | $6.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $14.67 | $10.83 |
| AVG Volume (30 Days) | 274.1K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.34 | ★ 100.00 |
| EPS | ★ 0.17 | 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $7.07 | $34.37 |
| Revenue Next Year | $2.81 | $22.86 |
| P/E Ratio | $66.65 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $9.55 | $4.30 |
| 52 Week High | $13.31 | $10.08 |
Technical Indicators
Market Signals| Indicator | ACEL | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 57.52 |
| Support Level | $10.82 | $6.26 |
| Resistance Level | $12.74 | $7.21 |
| Average True Range (ATR) | 0.34 | 0.27 |
| MACD | -0.11 | 0.04 |
| Stochastic Oscillator | 33.81 | 50.21 |
Price Performance
Historical ComparisonAbout ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.